A study showed that dopamine-norepinephrine reuptake inhibitor solriamfetol helps decrease excessive daytime sleepiness in patients with obstructive sleep apnea (OSA).
 |
| Photo: Obstructive Sleep Apnea (OSA) Patient | InStyleHealth |
The research conducted randomized patients to receive
12 weeks of placebo or solriamfetol at 37.5, 75, 150, or 300 mg/day. Efficacy
analysis was stratified by primary OSA therapy adherence. Coprimary endpoints were
week-12 change from baseline in Maintenance of Wakefulness Test (40-minute MWT)
and Epworth Sleepiness Scale (ESS).
There was a total of 324 (70.6%) participants were
treatment adherent (continuous airway pressure usage >4hours/night on
>70% nights, surgical intervention, or oral appliance use on >70%
nights), and 135 (29.4%) of patients were nonadherent.
Comparing it with placebo, solriamfetol dramatically reduced
excessive daytime sleepiness in patients. Average differences in MWT sleep
latency with the 37.5, 75, 150, and 300-mg groups were 4.8, 8.4, 10.2, and 12.5
minutes respectively among the adherent patients, while 3.7, 9.9, 11.9 and 13.5
minutes among the nonadherent patients.
Meanwhile, mean differences in the ESS in 37.5, 75,
150, and 300-mg cohort versus the placebo group were -2.4, -1.3, -4.2, and -4.7
among the adherent patients, and -0.7, -2.6, -5.0, and -4.6 among the nonadherent
patients separately.
However, prevalent reported adverse events or side
effects included headache, nausea, anxiety, decreased appetite, nasopharyngitis,
and diarrhea. Solriamfetol exerted no clinically changes in primary OSA therapy
use according to the research study. For complete details of the study, click
here.
Source: Chest 2021;doi:10.1016/j.chest.2021.02.033